The Ethical Problems of a Pharmaceutical Physician

  • M. D. B. Stephens

Abstract

Many major pharmaceutical companies of many nations, including the U.K. have been criticised for unethical behaviour in relation to ADR,288,289,290. The pharmaceutical industry has been criticised by Shapiro291 in the following terms: “I suggest, and in fact insist, that anyone engaged in the academic study of adverse reactions has to treat companies as potential adversaries, to maintain a distance from them and be reguired that any research must be independent of them”; and by Temple292 (Bureau of the F.D.A.), “Bias exists everywhere but the difference is that the bias of the drug industry is always in one direction”; by Fülgraff293 (President of the Bundesgesundheitsamtes): “Our experience is that many manufacturers are at least dangerous or ambiguous partners and they will continue to be so as long as they incline to the policy of appeasement against adverse reactions and to a purely defensive attitude in the reactions towards newly suspected ADRs”. In the 1983 meeting of the American Drug Information Association, Robert Temple, the acting Director of New Drug Evaluation, said whilst talking on the new regulation guidelines for New Drug Applications and referring to the form used for these applications (356H): “The form 356H also requires something called an evaluation of safety and effectiveness. That evaluation has to do some of the

Keywords

Marketing 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 288.
    Hansson, O. The voice of the consumer. In Drug Induced Sufferings. Medical, Pharmaceutical and Legal Aspects (ed. T. Soda), Excerpta Medica, Amsterdam, 1980, p.20Google Scholar
  2. 289.
    Nagarro, K., Onishi, Y. and Ozaki, J. Comparison of the drug affairs acts of different countries and problems of the amendment of the Japanese Drug Affairs Act in session. In Drug Induced Sufferings: Medical, Pharmaceutical and Legal Aspects (ed. T. Soda), Excerpta Medica, Amsterdam, 1980, p.281Google Scholar
  3. 290.
    Silverman, M. and Lydecker, M. Disclosures of hazards in international drug promotion. In Drug Induced Sufferings: Medical, Pharmaceutical and Legal Aspects (ed. T. Soda), Excerpta Medica, Amsterdam, 1980, pp.359–364Google Scholar
  4. 291.
    Shapiro, S. General discussion. In Drug Monitoring (ed. F.H. Gross and W.H.W. Inman), Academic Press, 1977, p.153Google Scholar
  5. 292.
    Temple, R. General discussion. In Drug Monitoring (ed. F.H. Gross and W.H.W. Inman), Academic Press, 1977, p.156Google Scholar
  6. 293.
    Fülgraff, G. General discussion. In Drug Monitoring (ed. F.H. Gross and W.H.W. Inman), Academic Press, 1977, p.156Google Scholar
  7. 294.
    Scrip, No 831, Sept. 21 1983, 12; No 854, Dec. 12, 1983, 5Google Scholar
  8. 295.
    Turner, P. Future trends in pharmaceutical medicine. In Pharmaceutical Medicine (ed. N. Macleod), Churchill Livingstone, 1978, p.156Google Scholar

Copyright information

© M.D.B. Stephens 1985

Authors and Affiliations

  • M. D. B. Stephens

There are no affiliations available

Personalised recommendations